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OBJECTIVE—Components of insulin/IGF-1 receptor–mediated sig-
naling pathways in pancreatic -cells have been implicated in the
development of diabetes, in part through the regulation of -cell mass
in vivo. Studies in vitro have shown that the protein Ras homolog
enriched in brain (Rheb) plays a key role as a positive upstream
regulator of the mammalian target of rapamycin complex 1 (mTORC1)
pathway in integrating inputs from nutrients and growth factors for cell
growth. Our objective was to investigate the role of the mTORC1
pathway in the regulation of -cell mass in vivo.
RESEARCH DESIGN AND METHODS—We generated trans-
genic mice that overexpress Rheb in -cells. We examined the
activation of the mTORC1 pathway and its effects on -cell mass, on
glucose metabolism, and on protection against hyperglycemia.
RESULTS—Immunoblots of islet extracts revealed that the
phosphorylation levels of ribosomal protein S6 and eukaryotic
initiation factor 4E binding protein 1, downstream effectors for
mTORC1, were upregulated in transgenic -cells. Immunostain-
ing of the pancreatic sections with anti–phospho-S6 antibody
conﬁrmed upregulation of the mTORC1 pathway in -cells in
vivo. The mice showed improved glucose tolerance with higher
insulin secretion. This arose from increased -cell mass accom-
panied by increased cell size. The mice also exhibited resistance
to hyperglycemia induced by streptozotocin and obesity.
CONCLUSIONS—Activation of the mTORC1 pathway by Rheb
led to increased -cell mass in this mouse model without
producing obvious unfavorable effects, giving a potential ap-
proach for the treatment of -cell failure and diabetes. Diabetes
58:1321–1332, 2009
D
iabetes arises from the relative failure of -cells
to secrete sufﬁcient insulin to maintain normal
metabolism (1). Under insulin-resistant condi-
tions such as obesity, blood glucose levels are
maintained within a normal range if the -cells can com-
pensate for the increased demand. This compensatory
mechanism is acquired by an increase in -cell mass
through augmentation of islet neogenesis and replication,
by hypertrophy, and by a reduction in the rate of -cell
death (2).
A number of studies have indicated that insulin and
IGF-1 receptor–mediated signaling pathways are involved
in the regulation of -cell mass (3–11). Activation of the
insulin or IGF-1 receptors induces tyrosine phosphoryla-
tion of insulin receptor substrates (IRSs), which recruit
several signal intermediates, including phosphoinositide-3
kinase. Phosphoinositide-3 kinase phosphorylates inositol
phospholipids, which then activates 3-phosphoinositide-
dependent kinase 1, which directly phosphorylates and
activates p70 S6 kinase and protein kinase B (PKB)
synergistically with mammalian target of rapamycin
(mTOR) (12–14). Ribosomal protein S6 and the transcrip-
tion factor forkhead box O1 (FoxO1), substrates of p70 S6
kinase (p70S6K) and PKB, respectively, are also impli-
cated in this process (15–17).
The Ser/Thr protein kinase mTOR signals through two
physically distinct multiprotein complexes called mTOR
complex (mTORC) 1 and 2 (12). mTORC1 contains the
polypeptides raptor and mLST8, and the ability of raptor to
present its substrates properly to the mTOR catalytic
domain is essential for the regulation of the translational
regulators eukaryotic initiation factor 4E binding protein 1
(4EBP1) and p70S6K (18,19). The proximal regulator of
mTORC1 is a Ras-like small GTPase named Ras homolog
enriched in brain (Rheb) (20,21). Rheb binds directly to
the mTOR catalytic domain and activates it in a manner
dependent on the state of Rheb nucleotide charging (22).
Insulin or IGF-1 enhances Rheb GTP charging via inhibi-
tion of the GTPase activating function of the product of
the tuberous sclerosis (TSC) genes, the TSC1–TSC2 het-
erodimer (23–31). The mTORC1 pathway is also regulated
by nutrients (32). Whereas amino acid depletion interferes
with the ability of Rheb to enable mTORC1 to attain an
active conﬁguration, glucose depletion reduces Rheb GTP
charging through the ability of the AMP-activated kinase to
phosphorylate TSC2 and to direct its GTPase-activating
activity toward Rheb (33,34). FKBP38 (FK506-binding pro-
tein 38) is also an endogenous inhibitor of mTOR whose
inhibitory activity is antagonized by Rheb in response to
growth factors and nutrient availability (35).
To investigate the metabolic role of the mTOR signaling
pathway in a mammalian model, we created transgenic
mice with an overproduction of Rheb in pancreatic -cells.
These mice exhibited increased insulin secretion in re-
sponse to glucose loading and resistance to streptozoto-
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accompanied by increased -cell mass.
RESEARCH DESIGN AND METHODS
A wild-type human Rheb gene tagged with a FLAG sequence at the NH2-
terminus was introduced downstream of the rat insulin promoter. The
transgene was microinjected into pronuclei of C57BL/6N zygotes. Mice
carrying the lethal yellow agouti (A
y) mutation were generated by breeding R3
transgenic mice with KK-A
y strain mice. The obtained F1 littermates carrying
the A
y mutation with or without a FLAG-Rheb transgene on C57BL/6 and a KK
hybrid background (designated A
y/Rheb and A
y) were analyzed. This study
was performed according to the guidelines of the animal ethics committee of
Kobe University Graduate School of Medicine.
Islet preparation and immunoblot analysis. Islets were isolated by
collagenase digestion followed by centrifugation over Histopaque medium
(Sigma-Aldrich, St. Louis, MO). Cultured islets were extracted in buffer A
(20 mmol/l Tris-HCl, pH 7.4, 120 mmol/l NaCl, 1 mmol/l EDTA, 5 mmol/l
EGTA, 50 mmol/l -glycerophosphate, 50 mmol/l NaF, 0.3% CHAPS, 1
mmol/l dithiothreitol, 4 g/ml leupeptin, and 4 g/ml aprotinin), and the
supernatants were analyzed by immunoblotting with the indicated antibod-
ies. The following antibodies were purchased from Cell Signaling Technol-
ogies (Beverly, MA): anti–phospho-S6 ribosomal protein (Ser235/236),
anti–S6 ribosomal protein, anti–phospho-4EBP1 (Thr37/46), anti–phospho-
4EBP1 (Thr70), anti–phospho-p70 S6 kinase (Thr389), anti-PKB, anti–
phospho-PKB (Ser473), anti–phospho-p44/42 mitogen-activated protein
(MAP) kinase (Thr202/Tyr204), and anti–p44/42 MAP kinase. Anti-IRS2
antibody was purchased from Upstate (Temecula, CA). Anti-Rheb antibody
was kindly provided by N. Oshiro (Biosignal Research Center, Kobe
University, Kobe, Japan).
Glucose tolerance testing and insulin tolerance testing. Mice were
deprived of food for 16 h, and blood was collected from the tail vein after an
oral injection (2 g/kg) or intraperitoneal injection (3 g/kg) of glucose. For
insulin tolerance testing, mice fed ad libitum were injected with 0.75 units/kg
body wt of human regular insulin.
Immunohistochemical and morphometric analysis of islets. Immuno-
staining for insulin and glucagon was performed using guinea pig antibod-
ies against insulin and rabbit antibodies against glucagon (Dako Japan,
C
D
B A
FIG. 1. Activation of the mTORC1 pathway by overexpression of FLAG-Rheb in pancreatic -cells. Islets isolated from mice of each genotype
were incubated either in 50% RPMI medium without FCS (A, B, and D) or in RPMI medium (C), or they were stimulated with 100 nmol/l
IGF-1 (B) or 15% FCS (D) as indicated. The same amounts of cellular extracts were analyzed by immunoblotting with the antibodies to
Rheb, phospho-S6 ribosomal protein (Ser235/236), S6 ribosomal protein, phospho-4EBP1 (Thr37/46 or Thr70), phospho-p70 S6 kinase
(Thr389), p70 S6 kinase, phospho-PKB (Ser473), PKB, phospho-p44/42 MAP kinase (Thr202/Tyr204), p44/42 MAP kinase, or IRS2. A
representative experiment is shown. The bottom panel in A shows the same blot as the top panel, except that it was exposed longer to detect
the endogenous Rheb (end-Rheb). E: Relative quantiﬁcation of phospho-S6 (Ser235/236), phospho-4EBP1 (T37/46 or T70), phospho-PKB
(Ser473), phospho-p44/42 MAP kinase (Thr202/Tyr204), and IRS2. The immunoblots were scanned, and the optical density for R3 with IGF1
or FCS stimulation (A, B, and D) or the optical density for R3 (C) was set to 100%. F: Immunoprecipitation with the anti-FLAG antibody
was performed using lysates of the hypothalamus, muscle, or liver isolated from mice of each genotype and analyzed by immunoblotting with
the same antibody. WT, wild type.
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antibodies conjugated with Cy3 or ﬂuorescein isothiocyanate, respectively
(Jackson ImmunoResearch Laboratories, West Grove, PA). For immuno-
staining of FLAG, phosphorylated S6, or Ki-67, after antigen retrieval by
autoclave at 121°C for 15 min in 10 mmol/l sodium citrate (pH 6.0) and
quenching of endogenous peroxidase with 3% H2O2 for 10 min, the sections
were incubated with the anti-FLAG antibody (DYKDDDDK Tag antibody;
Cell Signaling), anti–phospho-S6 ribosomal protein (Ser235/236), or anti–
Ki-67 antibody (Dako Japan). Immunocomplexes were detected with a
secondary antibody conjugated with horseradish peroxidase followed by
incubation in diaminobenzidine peroxidase substrate solution. The immu-
nostained sections were counterstained with hematoxylin. For quantiﬁca-
tion of -cell and -cell area, images of -o r-cells and of the entire
pancreas were obtained using a digital camera (BZ-8000; Keyence, Osaka,
Japan) and analyzed using WinROOF software (Mitani, Fukui, Japan). The
percentage of -o r-cell area was calculated as the area of all insulin- or
glucagon-positive cells based on the total pancreatic area surveyed. The
-cell mass was calculated by the percentage of -cell area and pancreas
weight. The relative -cell size was calculated by dividing the -cell area by
the number of -cell nuclei in the insulin-stained sections. Apoptotic
-cells were analyzed by immunostaining of insulin and terminal deoxy-
nucleotidyl transferase dUTP nick-end labeling (TUNEL) assay using an
ApopTag ﬂuorescein in situ apoptosis detection kit (Chemicon Interna-
tional, Temecula, CA) according to the manufacturer’s protocol.
Streptozotocin administration. Eight-week-old transgenic mice and wild-
type littermates were injected intraperitoneally for 5 consecutive days with
streptozotocin (40 mg/kg or 50 mg/kg) dissolved just before injection in 0.1
mol/l citrate buffer.
Rapamycin administration. Mice were injected intraperitoneally with rapa-
mycin (2 mg/kg) dissolved in 0.2% sodium carboxymethylcellulose and 0.25%
Tween 80 or control vehicle three times a week from 5 to 8 weeks of age.
Statistical analysis. Data are expressed as the means  SE and were
analyzed using the Mann-Whitney nonparametric U test. Two-tailed P values
of 0.05 were considered statistically signiﬁcant.
RESULTS
Expression of Rheb induces activation of the
mTORC1 pathway in pancreatic -cells. We conﬁrmed
the integration of the transgene in three independent
founder lines (R3, R20, and R35; accession no. CDB0441T).
Immunoblotting of total cellular extracts from pancreatic
islets using the anti-Rheb antibody demonstrated that the
transgene product was detected at a slightly higher level
than endogenous Rheb on SDS-PAGE (Fig. 1A). Similar
results were observed when FLAG-tagged Rheb was ex-
pressed transiently in HEK293 cells (data not shown),
suggesting that the addition of a FLAG sequence to Rheb
lowers the mobility of the polypeptide on SDS-PAGE.
Immunoprecipitation with the anti-FLAG antibody fol-
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FIG. 1. Continued.
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detect the expression of FLAG-Rheb in the hypothalamus,
muscle, or liver, indicating that the expression of FLAG-
Rheb is speciﬁc to the pancreatic -cells (Fig. 1F).
To conﬁrm the effect of the overexpression of Rheb in
-cells, we examined the phosphorylation of the down-
stream effectors for mTORC1, ribosomal protein S6, and
4EBP1. Because the mTORC1 pathway is regulated in a
nutrient-dependent manner, the ability of Rheb to activate
the mTORC1 pathway is most easily visualized in nutrient-
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FIG. 2. Metabolic effects of overexpression of Rheb in pancreatic -cells. A:
Growth curves of R3 or R20 lines of transgenic mice (F) and their wild-type
littermates (E). B: Blood glucose concentrations were measured in R3 and
R20 transgenic mice and their wild-type littermates in the fed state at 8 and
50 weeks. C: Plasma insulin concentrations were measured in R3 and R20
transgenic mice and their wild-type littermates in the fed state at 8 weeks.
D and E: Oral glucose tolerance tests were performed in R3 or R20
transgenic mice (F) and their wild-type littermates (E) at 8 weeks. Glucose
concentrations (D) and plasma insulin concentrations (E) are shown. F:
Oral glucose tolerance tests were performed in R20 transgenic mice (F)
and wild-type littermates (E) at 40 weeks. G: Intraperitoneal insulin
tolerance tests were performed in R20 transgenic mice (F) and wild-type
littermates (E). H: Intraperitoneal glucose tolerance tests were performed
in R20 transgenic mice (F) and wild-type littermates (E). Glucose concen-
trations and plasma insulin concentrations are shown. Data are the
means  SE of values from six (A), six to eight (B), eight (C), ﬁve (D and
E), six (F), nine (G), and six (H) animals from each genotype. *P < 0.05;
**P < 0.01. WT, wild type.
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were incubated for2hi n5 0 %RPMI medium that was
made by mixing RPMI with Krebs-Ringer bicarbonate
buffer without FCS. Phosphorylation of S6 (Ser235/236)
was clearly higher in islets prepared from transgenic mice
than in those prepared from wild-type littermates (Fig.
1A). The immunoreactivity of the anti–phospho-S6 anti-
body appeared to parallel the abundance of FLAG-Rheb.
The immunoreactivity of the anti–phospho-4EBP1 (Thr37/
46) antibody increased in the islets prepared from trans-
genic mice in the same manner. When islets were
stimulated with IGF-1, the immunoreactivities of the anti–
phospho-S6 and anti–phospho-4EBP1 (Thr37/46 and
Thr70) antibodies were increased in islets prepared from
wild-type littermates, but the extent of immunoreactivity
was still higher in islets from transgenic mice (Fig. 1B and
E). The immunoreactivity of the anti–phospho-PKB
(Ser473) was increased by IGF-1 stimulation in both
wild-type and transgenic islets; however, the stimulation
was greater in wild-type than in transgenic islets. The
amount of IRS2 appeared to be relatively reduced in the
transgenic islets compared with their wild-type littermates
(Fig. 1C). This might be caused by a possible negative
feedback mechanism induced by the activated p70 S6
kinase. Serum stimulation also induced phosphorylation
of S6 and 4EBP1, but the stimulation was still greater in
transgenic mice than in wild-type mice (Fig. 1D). Phos-
phorylation of MAPKs also increased after serum stimula-
tion, but the stimulation was similar in both wild-type and
transgenic islets. Subsequent studies were performed on
animals derived from founder lines R3 and R20.
Improved glucose tolerance in transgenic mice. The
rate of increase in body weight was not signiﬁcantly
different between the R3 and R20 lines of transgenic mice
and their wild-type littermates (Fig. 2A). Metabolic param-
eters, including plasma triglycerides, free fatty acids, and
leptin, were not signiﬁcantly different between R3 trans-
genic mice and wild-type littermates either (Table 1). In
contrast, R20 transgenic mice had signiﬁcantly lower
blood glucose concentrations in the fed state at 8 and 50
weeks compared with wild-type littermates (127.9  4.24
vs. 145.6  5.35 mg/dl at 8 weeks and 128.7  6.16 vs.
147.9  5.68 mg/dl at 50 weeks) (Fig. 2B). The plasma
insulin levels in R20 mice were 1.43-fold those of wild-type
littermates at 8 weeks (Fig. 2C). Although no signiﬁcant
differences in blood glucose concentrations were ob-
served between R3 transgenic mice and wild-type litter-
mates, the concentration tended to be lower in the
transgenic mice, and this tendency was maintained to 50
weeks. Oral glucose tolerance testing at 8 weeks revealed
that both the R3 and R20 lines of transgenic mice had
improved glucose tolerance compared with wild-type lit-
termates (Fig. 2D). Although fasting blood glucose con-
centrations were not signiﬁcantly different between
transgenic mice and wild-type littermates, both the R3 and
R20 lines of transgenic mice had signiﬁcantly lower blood
glucose levels after glucose loading. Insulin release in
response to glucose loading was signiﬁcantly higher in
transgenic mice than in wild-type littermates, with a
2.6-fold difference in R20 transgenic mice and a 1.7-fold
difference in R3 transgenic mice at 15 min after injection
(Fig. 2E). Similarly improved glucose tolerance was also
observed at 40 weeks with the R20 transgenic mice (Fig.
2F). In contrast, both R20 (Fig. 2G) and R3 transgenic mice
(data not shown) demonstrated similar insulin responsive-
ness after intraperitoneal injections of insulin. Then, intra-
peritoneal glucose tolerance testing was performed to
measure the in vivo glucose-stimulated insulin secretion in
the early and late phases (Fig. 2H). Although glucose
concentration did not differ signiﬁcantly between trans-
genic mice and wild-type littermates in the early phase, the
glucose concentration was signiﬁcantly lower in the trans-
genic mice in the late phase. Insulin secretion was similar
in transgenic mice and their wild-type littermates in the
early phase, but it was signiﬁcantly higher in transgenic
mice than in their wild-type littermates in the late phase.
Taken together, these results indicate that the improved
glucose tolerance in the transgenic mice can be attribut-
able mainly to a greater ability to secrete insulin in the late
phase.
ncreased -cell mass and cell growth in transgenic
mice. Hematoxylin and eosin staining of the sections
revealed that the pancreatic islet architecture was grossly
unchanged in mice from ages 8 to 90 weeks (Fig. 3A and
D). Immunostaining of the sections with the anti-FLAG
antibody conﬁrmed the expression of FLAG-Rheb in the
islets of transgenic mice from ages 8 to 90 weeks (Fig. 3B
and D). Immunostaining with the anti–phospho-S6 anti-
body appeared lower in the islet areas than in the exocrine
acinar areas. However, the dark-staining cells in the islets
appeared more abundant in transgenic mice than in the
wild-type littermates (Fig. 3C). The ratio of the number of
the dark staining cells to the number of nuclei in the islets
was signiﬁcantly higher in transgenic mice than in wild-
type littermates (19.48  3.23 vs. 6.76  1.14%).
Immunostaining with the anti-insulin and anti-glucagon
antibodies also demonstrated the grossly unchanged struc-
tures of pancreatic islets (Fig. 3E). Quantitative determi-
nation of -cell area relative to pancreatic area in insulin-
stained sections revealed that the -cell area was
signiﬁcantly higher (1.46-fold) in R3 transgenic mice than
in wild-type littermates (0.581  0.048 vs. 0.399  0.040%)
(Fig. 3F). In contrast, the -cell area did not differ signif-
icantly between the R3 transgenic and wild-type litter-
mates (0.144  0.028 vs. 0.134  0.018%). -Cell mass was
also signiﬁcantly increased in R3 transgenic mice com-
pared with wild-type littermates (1,070  63.6 vs. 712.5 
60.9 g) (Fig. 3G). The relative -cell size was signiﬁcantly
increased at 1.30-fold in the transgenic mice compared
with wild-type littermates (253.7  14.56 vs. 197.6  5.0
m
2) (Fig. 3H). To evaluate the involvement of -cell
proliferation in the increase of -cell mass in the trans-
genic mice, immunostaining with the anti–Ki-67 antibody
was performed (Fig. 3I). As shown in Table 2, we did not
observe signiﬁcant differences in the proportion of Ki-67–
positive nuclei in the islets between wild-type and trans-
genic mice. To evaluate the involvement of apoptotic
-cells, TUNEL assay was performed but could not detect
signiﬁcant amounts of apoptotic cells at the basal state.
TABLE 1
Metabolic characteristics of the transgenic mice and their wild-
type littermates
Plasma free
fatty acids
(mg/dl)
Plasma
triglycerides
(mg/dl)
Plasma
leptin
(ng/ml)
Wild type 1.46  0.13 154.6  9.4 2.09  0.30
Transgenic 1.44  0.77 166.8  16.6 1.57  0.21
Data are means  SE of values from 7–10 animals from each
genotype at 8 weeks for plasma triglycerides and leptin or at 10
weeks for plasma free fatty acids.
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FIG. 3. Increased -cell mass and cell growth in transgenic mice. A: Hematoxylin and eosin staining of representative pancreatic sections from
8-week-old R3 transgenic mice and their wild-type littermates. B and C: Immunostaining with the anti-FLAG antibody (B) and anti–phospho-S6
(Ser235/236) antibody (C, upper panels) of representative pancreatic sections from 8-week-old R3 transgenic mice and wild-type littermates.
Ratio of the number of dark staining cells to the total number of nuclei in islets from transgenic mice and wild-type littermates is shown (C, lower
panels). D: Hematoxylin and eosin (H-E) staining and immunostaining with the anti-FLAG antibody of representative pancreatic sections from
90-week-old R3 transgenic mice and their wild-type littermates. E: Immunostaining with the anti-insulin (red) and the anti-glucagon (green)
antibodies of representative pancreatic sections from 8-week-old R3 transgenic mice and their wild-type littermates. F: Quantiﬁcation of - and
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hyperglycemia in transgenic mice. To determine
whether Rheb overexpression in pancreatic -cells pre-
vented hyperglycemia in pathophysiological conditions,
we used two models of experimentally induced diabetes:
streptozotocin-induced and obesity-induced. First, R3 line
transgenic mice and wild-type littermates were subjected
to intraperitoneal injections of streptozotocin at 40 or 50
mg/kg for 5 consecutive days. Monitoring of blood glucose
levels in the fed state revealed that wild-type littermates
had signiﬁcant hyperglycemia by 1 or 3 weeks after
starting injections at doses of 50 or 40 mg/kg, respectively.
By contrast, R3 transgenic mice remained resistant to
hyperglycemia (175.5  13.5 vs. 135.3  8.87 mg/dl at 40
mg/kg, and 327.0  2.27 vs. 156.8  7.52 mg/dl at 50 mg/kg
4 weeks after injection) (Fig. 4A). R20 line transgenic mice
also exhibited the same resistance to hyperglycemia in-
duced by streptozotocin as the R3 transgenic mice (Fig.
4B). The insulin level of the wild-type and transgenic mice
decreased to 25.3 and 33.4%, respectively, of the levels in
the nontreated wild-type and transgenic mice of the same
age (Fig. 4C). However, the glucose-to-insulin ratio dif-
fered signiﬁcantly between transgenic mice and their
wild-type littermates 4 weeks after injection (4.79  0.51 
10
6 wt/wt vs. 16.34  4.93  10
6 wt/wt) (Fig. 4D). Because
the insulin sensitivity did not differ between wild-type and
transgenic mice, as described above, the signiﬁcant differ-
ence in the glucose-to-insulin ratios suggests that the
amount of insulin secreted in response to blood glucose
concentration differed between groups. Oral glucose tol-
erance testing demonstrated clearly that transgenic mice
were able to secrete more insulin than wild-type litter-
mates in response to glucose loading (Fig. 4E), although
the maximum production of insulin was reduced even in
transgenic mice when compared with the results shown in
Fig. 2E. Consistent with the decrease in the serum insulin
levels, immunohistological analysis demonstrated that
-cell areas were decreased in both transgenic mice and
wild-type littermates compared with nontreated mice.
However, the -cell area was signiﬁcantly higher in trans-
genic mice than in wild-type littermates (0.340  0.025 vs.
0.243  0.030%) (Fig. 4F and G). TUNEL staining of the
pancreatic sections showed no signiﬁcant difference in the
extent of apoptosis in -cells 1 week after administration
with streptozotocin (Fig. 4H and Table 3).
Second, as a model of obesity-induced diabetes, we
generated R3 transgenic mice with the lethal yellow agouti
(A
y) mutation by breeding R3 transgenic mice with KK-A
y
mice. For analysis we used F1 offspring littermates carry-
ing the A
y mutation with or without a FLAG-Rheb trans-
gene on a C57BL/6 and KK mouse strain hybrid
background (designated A
y/Rheb and A
y, respectively).
The rate of increase in body weight was not signiﬁcantly
different between A
y/Rheb and A
y mice (35.5  0.94 vs.
37.5  1.06 g at 10 weeks). Oral glucose tolerance testing
revealed that the A
y/Rheb mice had improved glucose
tolerance (Fig. 5A). Although blood glucose concentra-
tions in the fasting state were not signiﬁcantly different
between A
y/Rheb and A
y mice, the A
y/Rheb mice had
signiﬁcantly lower blood glucose levels at 60 and 120 min
after glucose loading. Thus, the glucose concentration in
A
y mice remained at 424  39.8 mg/dl at 60 min and
363.4  47.9 mg/dl at 120 min, whereas that in A
y/Rheb
mice was 210  46.6 mg/dl at 60 min and returned to
116.2  17.91 mg/dl at 120 min. The improved glucose
tolerance in A
y/Rheb mice was attributable to higher
insulin release, with a signiﬁcant 2.2-fold level at 15 min
and a 1.9-fold level at 30 min after glucose loading com-
pared with A
y mice.
Elimination of the effect of Rheb expression by the
administration with rapamycin. To examine whether
the phenotypes observed above are dependent on the
mTORC1 pathway, mice were injected intraperitoneally
with mTORC1 inhibitor rapamycin from 5 to 8 weeks of
age, and glucose tolerance testing was performed at 8
weeks (Fig. 5B). At 15, 30, 60, and 120 min after glucose
loading, blood glucose concentration was  50 mg/dl
higher in rapamycin-treated mice than in untreated mice.
Notably, glucose tolerance was similar in rapamycin-
treated transgenic mice and in rapamycin-treated wild-
type littermates. In addition, the improved insulin
secretion in transgenic mice was eliminated completely to
the level observed in their wild-type littermates. Immuno-
blot analysis of the islets prepared from rapamycin- or
vehicle-treated mice demonstrated that phosphorylation
of S6 and 4EBP1 were reduced by rapamycin administra-
tion in both transgenic mice and wild-type littermates,
indicating that the effect of rapamycin was achieved by
suppression of mTORC1 activity (Fig. 5C).
-cell area as a percentage of total pancreatic area in transgenic mice and their wild-type littermates. G: -Cell mass was calculated by the -cell
area and pancreas weight. H: The relative size of -cells in the transgenic mice and their wild-type littermates was calculated. I: Immunostaining
with anti–Ki-67 antibody of representative pancreatic sections from 9-week-old R3 transgenic mice and their wild-type littermates. Data are the
means  SE of values from four (C), ﬁve (F), four (G), and ﬁve (H) animals from each genotype. *P < 0.05; **P < 0.01. WT, wild type. (A
high-quality digital representation of this ﬁgure is available in the online issue.)
TABLE 2
Numbers of total and Ki-67–positive nuclei in islets
Counted
islets per
animal
Counted
nuclei per
animal
Nuclei
per islet
Proportion of
Ki-67–positive
nuclei per
islet (%)
Wild type 68 6,297  664.5 93  7.6 1.10  0.08
Transgenic 60 5,291  567.7 89  9.7 1.16  0.13
Data are means  SE of values from four animals from each
genotype. Pancreatic sections were immunostained with the anti–
Ki-67 antibody followed by counterstaining with hematoxylin as
shown in Fig. 3I. Numbers of all nuclei and of Ki-67–positive nuclei
in the islets of wild-type and transgenic mice were counted.
TABLE 3
Numbers of insulin- and TUNEL-positive nuclei in islets
Counted
islets per
animal
Counted
nuclei per
animal
Nuclei
per islet
Proportion of
TUNEL-positive
nuclei per islet
(%)
Wild type 69 2,882  567.8 43  4.3 0.55  0.15
Transgenic 65 3,233  495.5 46  4.0 0.42  0.11
Data are means  SE of values from ﬁve animals from each
genotype. Pancreatic sections were double-stained with the anti-
insulin antibody and TUNEL assay 1 week after 50 mg/kg streptozo-
tocin administration as shown in Fig. 4H. Numbers of all nuclei and
of TUNEL-positive nuclei in the insulin-positive cells of wild-type and
transgenic mice were counted.
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FIG. 4. Transgenic mice were resistant to streptozotocin-induced hyperglycemia. A: Doses of 40 mg/kg or 50 mg/kg streptozotocin were
administered to R3 line transgenic mice (F) or wild-type littermates (E) for 5 consecutive days (arrows in the ﬁgure). Blood glucose
concentrations in the fed state were monitored. Data are the means  SE of values from four (40 mg/kg) or ﬁve (50 mg/kg) animals from each
genotype. B: A dose of 50 mg/kg streptozotocin was administered to R20 transgenic mice (F) or wild-type littermates (E), and blood glucose
concentrations were monitored with mice in the fed state. Data are the means  SE of values from four animals from each genotype. C and D:
Plasma insulin concentration (C) and glucose-to-insulin ratio (D) after administration with or without 50 mg/kg streptozotocin as shown in A.
E: Oral glucose tolerance tests were performed in R20 transgenic mice (F) and wild-type littermates (E) 4 weeks after streptozotocin
administration as shown in B. Glucose and insulin concentrations are shown. F: Immunostaining with the anti-insulin (red) and anti-glucagon
(green) antibodies of representative pancreatic sections from R3 transgenic mice (R3) and their wild-type littermates (WT) 4 weeks after 50
mg/kg streptozotocin administration as shown in A. G: Quantiﬁcation of -cell area as a percentage of total pancreatic area in transgenic mice
and their wild-type littermates 4 weeks after administration with or without 50 mg/kg streptozotocin as shown in A. H: Immunostaining with
anti-insulin (red) antibody and TUNEL assay (green) of representative pancreatic sections from the transgenic mice and their wild-type
littermates 1 week after 50 mg/kg streptozotocin administration. Values represent the means  SE. *P < 0.05; **P < 0.01. (A high-quality digital
representation of this ﬁgure is available in the online issue.)
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To examine the role of the mTORC1 pathway in pancreatic
-cells in vivo, we produced transgenic mice that express
Rheb under the control of the rat insulin promoter. Rheb is
unique in that it maintains basal levels of GTP charging
much higher than those of Ras because of its lower
intrinsic GTPase activity. With a limiting level of endoge-
nous Rheb GTPase-activating activity established by the
TSC complex, even wild-type Rheb takes an active GTP
form when it is overexpressed (21). When isolated islets
were incubated in nutrient-limited media, phosphorylation
levels of ribosomal protein S6 and of 4EBP1 were clearly
augmented in transgenic -cells compared with wild-type
-cells, in parallel with the abundance of FLAG-Rheb.
Moreover, immunostaining of the pancreas sections with
the anti–phospho-S6 antibody revealed an increase in S6
phosphorylation in the transgenic -cells. These results
indicate that the mTORC1 pathway is upregulated in the
pancreatic -cells of transgenic mice in vivo as well as in
vitro.
We found that these transgenic mice had improved
glucose tolerance because of a higher capacity to secrete
insulin in response to glucose loading. We also found that
the increase in insulin secretion was mediated mainly by
the increased secretion in the late phase. Morphometry
proved that the increase in the capacity to produce insulin
could be attributed to an increase in the -cell mass, which
was accompanied by increased -cell size. These results
are consistent with previous reports that overexpression
of Rheb as well as loss-of-function mutations of the genes
encoding TSC1 or TSC2 results in enlarged cell size
(23–28,36).
Overexpression of Rheb might induce dysfunction of
-cells because inappropriate activation of the TSC/Rheb
pathway leads to the downregulation of the insulin/IGF-1
signaling system as a result of degradation of IRS1 and -2
(37–41). Moreover, constitutive activation of the mTOR
pathway by loss of the TSC1 or TSC2 genes in cell lines
and tumors causes endoplasmic reticulum stress, resulting
in inhibition of insulin action and an increase in vulnera-
bility to apoptosis (42). Consistent with these reports,
Shigeyama et al. (43) demonstrated that mice deﬁcient in
TSC2 in pancreatic -cells developed progressive hyper-
glycemia after 40 weeks of age, although the mice also
exhibited hypoglycemia and hyperinsulinemia when
young, suggesting that downregulation of insulin action or
endoplasmic reticulum stress might occur with aging. By
contrast, transgenic mice tended to have lower glucose
levels and improved glucose tolerance even at 40–50
weeks. The histological analysis of islets of even 90-week-
old mice conﬁrmed no adverse effect on pancreatic -cells.
Although the IRS2 level appeared to be relatively reduced
in transgenic islets, the extent of the mTORC1 activation
might not be strong enough to induce adverse effects on
the -cells in these transgenic mice.
Upregulation of IRS2 and Akt or deletion of Pten in-
duces an increase in -cell mass and resistance to hyper-
glycemia (6,7,44). A similar phenotype has been reported
for the downregulation of more distal negative mediators
of Akt, FoxO1, and p27
kip1 (15,16,45). These phenotypes
are mediated by increased proliferation of -cells as well
as an increase in -cell size. Reciprocally, mice deﬁcient
for p70S6K or knock-in mice whose S6 protein contains
alanine substitutions at all ﬁve phosphorylatable serine resi-
dues sites show reduced insulin secretion in response to
glucose caused by diminished -cell size (5,17). Because
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y/Rheb mice (F) and
A
y littermates (E). Blood glucose concentrations and plasma insulin concentrations are shown. B: Elimination of the effect of Rheb expression
in -cells after administration with rapamycin. Oral glucose tolerance tests were performed in rapamycin-treated transgenic mice (F) and their
rapamycin-treated wild-type littermates (E). Blood glucose and plasma insulin concentrations are shown. Data are the means  SE of values from
ﬁve (A and B) animals from each genotype. C: Islets were prepared from rapamycin- or vehicle-treated mice of each genotype and incubated for
1 h in RPMI, and the same amounts of cellular extracts were analyzed by immunoblotting with the antibodies to phospho-S6 ribosomal protein
(Ser235/236), phospho-4EBP1 (Thr37/46), or S6 ribosomal protein. *P < 0.05; **P < 0.01. WT, wild type.
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progression and cell growth in Drosophila (28), and be-
cause mTORC1 is involved in cell proliferation in some
mammalian cells such as cancer cells, it might be prema-
ture to conclude only from Ki-67 staining that cell prolif-
eration is not involved in our mouse model.
It should be noted that transgenic mice exhibited resis-
tance to hyperglycemia induced by low-dose streptozoto-
cin as well as by obesity. Although streptozotocin
administration induced a reduction of -cell areas by
43–45% in both wild-type and transgenic mice, insulin
secretion in response to glucose loading was much higher
in transgenic mice than in wild-type littermates. This
suggests that the residual -cell function in transgenic
mice might be higher than that in wild-type littermates.
We cannot exclude completely the possibility that over-
expression of Rheb might affect intracellular signals other
than mTORC1 pathways. Rheb has been reported to
inhibit the Raf-dependent MAPK pathway through the
interaction of the Ras-binding domain of BRaf or cRaf in a
rapamycin-insensitive manner (46–48). However, serum
stimulation of MAPK phosphorylation did not appear to
decrease in the transgenic islets compared with their
wild-type littermates. In addition, rapamycin administra-
tion eliminated the improved insulin secretion in the
transgenic mice completely to the level observed in wild-
type littermates. Given that MAPKs are not affected signif-
icantly by rapamycin, these results suggest that the
rapamycin-sensitive mTORC1 pathway plays a crucial role
in this mouse model.
In conclusion, our ﬁndings highlight the importance of
the role of the mTORC1 pathway in pancreatic -cells.
Activation of the mTORC1 pathway by Rheb led to an
increase in -cell mass and protection from hyperglycemia
induced by -cell injury and by insulin resistance. Further
elucidation of the intracellular signaling mediated by Rheb
in pancreatic -cells might thus provide a basis for the
development of new therapeutic strategies to improve
insulin secretion and thereby prevent the development of
diabetes.
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